NCT07154706
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07154706
Title Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Acronym TRUST-IV
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Nuvation Bio Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Georgetown University Medical Cener (GUMC) RECRUITING Washington D.C. District of Columbia 20007 United States Details
Saint Alphonsus Health System RECRUITING Boise Idaho 83706 United States Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
Mayo Clinic RECRUITING Rochester Minnesota 55905 United States Details
Memorial Sloan Kettering Cancer Center RECRUITING New York New York 10065 United States Details
Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South RECRUITING Austin Texas 78731 United States Details
MD Anderson RECRUITING Houston Texas 45559 United States Details
Virginia Cancer Specialists RECRUITING Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field